Spondyloarthritis & psoriatic arthritis
Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
Authors' conclusion
The ASAS HI demonstrated reliability, construct validity, known groups discrimination, and responsiveness in adults with r-axSpA in 2 clinical trials.
Study context
- Population
- Patients with radiographic axial spondyloarthritis (r-axSpA) in ixekizumab trials
- Participants
- 341 vs 316
- Comparison
- COAST-V vs COAST-W
- COAST-Vn = 341
- COAST-Wn = 316
- Outcome
- ASAS HI clinimetric properties
Methodological detailssecondary analysis of 2 randomised controlled trials, data from 2 randomized, placebo-controlled, active-controlled phase III trials (COAST-V, COAST-W)
- Secondary analysis of 2 randomised controlled trials
- Data from 2 randomized, placebo-controlled, active-controlled phase III trials (COAST-V, COAST-W)
Performance
As reported in the abstract
| Test or model | ICC test-retest reliability |
|---|---|
| COAST-V | 0.78 |
| COAST-W | 0.76 |
ICC test-retest reliability
COAST-V0.78
COAST-W0.76
- Correlation between ASAS HI and BASDAI (moderate-to-large)
- r = 0.40-0.61
- Differences in mean ASAS HI between ASDAS disease activity categories at baseline and week 16
- all P < 0.001
- ASAS HI differentiated between ASAS, BASDAI and ASDAS response groups
- P < 0.001
Original publication
Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials. J Rheumatol. Published 1 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →